BridgeBio Pharma, Inc. Amortization of Intangible Assets
BridgeBio Pharma, Inc. (BBIO) reported Amortization of Intangible Assets of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-10
- BridgeBio Pharma, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $700.00K, a 0.00% change year-over-year.
- BridgeBio Pharma, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $700.00K, a 16.67% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $700.00K, a 16.67% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $700.00K, a 16.67% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of intangible assets for fiscal 2025 was $2.70M, a 12.50% increase from fiscal 2024.
- BridgeBio Pharma, Inc. amortization of intangible assets for fiscal 2024 was $2.40M, a 0.00% change from fiscal 2023.
- BridgeBio Pharma, Inc. amortization of intangible assets for fiscal 2023 was $2.40M, a 0.00% change from fiscal 2022.
- BridgeBio Pharma, Inc. amortization of intangible assets for fiscal 2022 was $2.40M, a 7.69% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-10 | $1.40M 10-Q · filed 2026-08-10 | $2.10M derived: sum of 3 quarters · filed 2026-08-10 | $2.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-07 | $1.40M derived: sum of 2 quarters · filed 2026-05-07 | $2.10M derived: sum of 3 quarters · filed 2026-05-07 | $2.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.40M derived: sum of 2 quarters · filed 2026-02-24 | $2.10M derived: sum of 3 quarters · filed 2026-08-10 | $2.70M 10-K · filed 2026-02-24 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-10-29 | $1.40M derived: sum of 2 quarters · filed 2026-08-10 | $2.00M 10-Q · filed 2025-10-29 | $2.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $700.00K 10-Q · filed 2026-08-10 | $1.30M 10-Q · filed 2026-08-10 | $1.90M derived: sum of 3 quarters · filed 2026-08-10 | $2.50M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-07 | $1.20M derived: sum of 2 quarters · filed 2026-05-07 | $1.80M derived: sum of 3 quarters · filed 2026-05-07 | $2.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.80M derived: sum of 3 quarters · filed 2026-02-24 | $2.40M 10-K · filed 2026-02-24 |
| 2024-09-30 | $600.00K 10-Q · filed 2025-10-29 | $1.20M derived: sum of 2 quarters · filed 2025-10-29 | $1.80M 10-Q · filed 2025-10-29 | $2.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-05 | $1.20M 10-Q · filed 2025-08-05 | $1.80M derived: sum of 3 quarters · filed 2026-02-24 | $2.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $600.00K 10-Q · filed 2025-04-29 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.80M derived: sum of 3 quarters · filed 2026-02-24 | $2.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.80M derived: sum of 3 quarters · filed 2026-02-24 | $2.40M 10-K · filed 2026-02-24 |
| 2023-09-30 | $600.00K 10-Q · filed 2024-11-12 | $1.20M derived: sum of 2 quarters · filed 2024-11-12 | $1.80M 10-Q · filed 2024-11-12 | $2.40M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-01 | $1.20M 10-Q · filed 2024-08-01 | $1.80M derived: sum of 3 quarters · filed 2025-02-20 | $2.40M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-02 | $1.20M derived: sum of 2 quarters · filed 2025-02-20 | $1.80M derived: sum of 3 quarters · filed 2025-02-20 | $2.40M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.20M derived: sum of 2 quarters · filed 2025-02-20 | $1.80M derived: sum of 3 quarters · filed 2025-02-20 | $2.40M 10-K · filed 2025-02-20 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-02 | $1.20M derived: sum of 2 quarters · filed 2023-11-02 | $1.80M 10-Q · filed 2023-11-02 | $3.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-03 | $1.20M 10-Q · filed 2023-08-03 | $2.80M derived: sum of 3 quarters · filed 2024-02-22 | $3.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-04 | $2.20M derived: sum of 2 quarters · filed 2024-02-22 | $2.90M derived: sum of 3 quarters · filed 2024-02-22 | |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.00M derived: sum of 2 quarters · filed 2024-02-22 | $2.60M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $700.00K 10-Q · filed 2021-11-04 | $1.30M 10-Q · filed 2021-11-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |